Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c24684033fba97d1ad845ce453a57e3 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-64 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 |
filingDate |
1980-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ddb983065e0fdeb3a250e19cf6a5c2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f9fa907f166b37145e056823507aa19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdf4b777e3d982c6a0892f521c3ef450 |
publicationDate |
1981-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
DE-3011153-A1 |
titleOfInvention |
USE OF N- (4-TIP CLAMP ON 2- (5-CHLORINE-2-METHOXY-BENZAMIDO) -ETHYL TIP CLAMP TO -BENZOLSULFONYL) -N'-METHYL UREA |
abstract |
Use of N-/4-/2-(5-chloro-2-methoxybenzamido) ethyl/ benzenesulphonyl/ -N'-methylurea (I) and its physiologically tolerable salts of normalising the serum insulin level is new. (I) (a known hypoglycaemic agent - see DE2413514) lowers supranormal insulin serum levels. In addn., (I) potentiates the nutrition-induced increase in insulin level when the serum insulin level is subnormal or is at the normal basal level. (I) is accordingly suitable for the treatment of maturity onset diabetes, as well as for use in the treatment of overweight patients with hyperinsulinism. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6335467-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-700883-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5607976-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5776980-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6506937-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6090981-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5574069-A |
priorityDate |
1980-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |